Webcasts
Drug Digest: Changes and Trends in the Outsourcing Landscape (2024)
In this episode of Drug Digest, Eric S. Langer, president and managing partner, BioPlan Associates discusses the current outsourcing landscape in the post-COVID world and the changes the pandemic has enforced in the demand for outsourced bioprocessing services.
Discovery Matters Podcast with CPhI (2021)
Dodi Axelson, Discovery Matters Podcast with CPhI talks with Eric Langer, Managing Partner of BioPlan Associates, about BioPlan’s Annual Report on Biopharmaceutical Manufacturing Capacity and Production.
China's Emergence in Global Biopharma Manufacturing: Trends in the Chinese Biopharma Series (2018)
This four-part educational series, sponsored by BioProcess International and BioPlan Associates, Inc., highlights key trends emerging in China biopharmaceuticals, using select content from BioPlan Associates’ 2018 2nd edition report, Advances in Biopharmaceutical Technology in China, 2nd Ed., a unique, peer-reviewed study that incorporates the research and work from over 100 global industry expert authors, many based in China.
China Biopharma Opportunities – Watch Now
In Part 1, Michael Frizberg, President, CMAB – Switzerland and Hong Kong, highlights key drivers and areas of growth in China biopharma today, as well as cover areas of opportunities for expansion and revenue in today’s markets.
China Biopharma – A Hot Bed for Investments – Watch Now
In Part 2, Dr. Linda Pullan, Principal, Pullan Consulting, covers China investments, as well as advice for negotiating China deals.
In Part 3, Fai Poon, President, QuaCell Biotech, Ltd., covers China regulatory issues, a review of current challenges in biopharma quality management in China, and opportunities for progress with growing CMO platforms and emerging CQO business.
In Part 4, Dr. Scott Wheelwright, Co-Founder and Principal, Complya Asia, provides an overview of factors affecting manufacturing, manufacturing trends by market, biopharmaceutical manufacturing in China among CMOs and developing companies.